Newsroom

Strive to Deliver Breakthroughs

  1. June 27, 2022

    Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — June 27, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that the U.S. Food and Dr...

    View more
  2. June 08, 2022

    Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — June 8, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that China National Medica...

    View more
  3. June 01, 2022

    Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — Jun 1, 2022   Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical ...

    View more
  4. May 25, 2022

    Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 25, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successfully ...

    View more
  5. May 10, 2022

    Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 10, 2022   Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical...

    View more
  6. May 06, 2022

    Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 6, 2022   Harbour BioMed (“HBM”, HKEX:02142), a global biopharmaceutical company co...

    View more
  7. April 14, 2022

    Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

    CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - April 14, 2022   Harbour BioMed (“HBM” or the “Company”; HKEX: 021...

    View more
  8. April 07, 2022

    Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— April 7, 2022   Harbour BioMed (“HBM”, “the Company”, HKEX: 02142), a globa...

    View more
  9. April 06, 2022

    Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— April 6, 2022   Harbour BioMed (“HBM”, HKEX: 02142), a global biopharmaceutical company ...

    View more
  10. March 25, 2022

    Harbour BioMed Reports Full Year 2021 Financial Results: Two Late-stage Programs Are Accelerating Towards Commercialization with Robust Innovation and Globalization Capabilities

    CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - March 25, 2022   Harbour BioMed (“HBM” or the “Company”; HKEX: 021...

    View more